CJC-1295

CJC-1295 is a synthetic peptide that acts as an analog of growth hormone-releasing hormone (GHRH), and its prolonged effects on stimulating growth hormone (GH) and insulin-like growth factor I secretion make it notable in both medical research and illicit use.

Indexed studies highlight CJC-1295's ability to significantly extend the stimulation of GH and related factors, which has implications for therapeutic applications such as orthopaedic treatments. However, its use extends beyond legitimate medical settings; it is also used by some individuals outside clinical guidance, particularly among female users who seek enhanced physical performance or appearance.

Connections to other peptides and growth hormone analogs are strong due to shared mechanisms of action and regulatory concerns. Additionally, there is a link to doping in equine sports where testing methods have been developed specifically for detecting CJC-1295 abuse.

The evidence base, while informative about its effects and detection methods, remains limited in terms of long-term safety and efficacy outside controlled clinical settings.

Sources

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. (PMID:16352683)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. (PMID:26771670)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (PMID:41490200)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. (PMID:30938069)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. (PMID:41476424)
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. (PMID:30489688)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._